501 related articles for article (PubMed ID: 15347726)
1. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy.
Kang JH; Chung JK; Lee YJ; Shin JH; Jeong JM; Lee DS; Lee MC
J Nucl Med; 2004 Sep; 45(9):1571-6. PubMed ID: 15347726
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo.
Zuckier LS; Dohan O; Li Y; Chang CJ; Carrasco N; Dadachova E
J Nucl Med; 2004 Mar; 45(3):500-7. PubMed ID: 15001694
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene.
Lee YJ; Chung JK; Shin JH; Kang JH; Jeong JM; Lee DS; Lee MC
Thyroid; 2004 Nov; 14(11):889-95. PubMed ID: 15671766
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene.
Chen L; Altmann A; Mier W; Eskerski H; Leotta K; Guo L; Zhu R; Haberkorn U
J Nucl Med; 2006 May; 47(5):854-62. PubMed ID: 16644756
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression.
Chen L; Altman A; Mier W; Lu H; Zhu R; Haberkorn U
Nucl Med Biol; 2006 May; 33(4):575-80. PubMed ID: 16720251
[TBL] [Abstract][Full Text] [Related]
6. Visualization of endogenous p53-mediated transcription in vivo using sodium iodide symporter.
Kim KI; Chung JK; Kang JH; Lee YJ; Shin JH; Oh HJ; Jeong JM; Lee DS; Lee MC
Clin Cancer Res; 2005 Jan; 11(1):123-8. PubMed ID: 15671536
[TBL] [Abstract][Full Text] [Related]
7. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.
Schipper ML; Riese CGU; Seitz S; Weber A; Béhé M; Schurrat T; Schramm N; Keil B; Alfke H; Behr TM
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):638-650. PubMed ID: 17160413
[TBL] [Abstract][Full Text] [Related]
9. Development of a dual membrane protein reporter system using sodium iodide symporter and mutant dopamine D2 receptor transgenes.
Hwang DW; Kang JH; Chang YS; Jeong JM; Chung JK; Lee MC; Kim S; Lee DS
J Nucl Med; 2007 Apr; 48(4):588-95. PubMed ID: 17401096
[TBL] [Abstract][Full Text] [Related]
10. Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes.
Urnauer S; Klutz K; Grünwald GK; Morys S; Schwenk N; Zach C; Gildehaus FJ; Rödl W; Ogris M; Wagner E; Spitzweg C
J Gene Med; 2017 May; 19(5):. PubMed ID: 28423213
[TBL] [Abstract][Full Text] [Related]
11. In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.
Shi S; Zhang M; Guo R; Miao Y; Hu J; Xi Y; Li B
PLoS One; 2015; 10(1):e0116531. PubMed ID: 25621996
[TBL] [Abstract][Full Text] [Related]
12. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
Ma XJ; Huang R; Kuang AR
Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193
[TBL] [Abstract][Full Text] [Related]
13. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
[TBL] [Abstract][Full Text] [Related]
14. Development of a sodium/iodide symporter (NIS)-transgenic mouse for imaging of cardiomyocyte-specific reporter gene expression.
Kang JH; Lee DS; Paeng JC; Lee JS; Kim YH; Lee YJ; Hwang DW; Jeong JM; Lim SM; Chung JK; Lee MC
J Nucl Med; 2005 Mar; 46(3):479-83. PubMed ID: 15750162
[TBL] [Abstract][Full Text] [Related]
15. Reversing the silencing of reporter sodium/iodide symporter transgene for stem cell tracking.
Kim YH; Lee DS; Kang JH; Lee YJ; Chung JK; Roh JK; Kim SU; Lee MC
J Nucl Med; 2005 Feb; 46(2):305-11. PubMed ID: 15695791
[TBL] [Abstract][Full Text] [Related]
16. Combined radionuclide-chemotherapy and in vivo imaging of hepatocellular carcinoma cells after transfection of a triple-gene construct, NIS, HSV1-sr39tk, and EGFP.
Lee YL; Lee YJ; Ahn SJ; Choi TH; Moon BS; Cheon GJ; Lee SW; Ahn BC; Ha JH; Lee J
Cancer Lett; 2010 Apr; 290(1):129-38. PubMed ID: 19819065
[TBL] [Abstract][Full Text] [Related]
17. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
Spitzweg C; Baker CH; Bergert ER; O'Connor MK; Morris JC
Hum Gene Ther; 2007 Oct; 18(10):916-24. PubMed ID: 17931047
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein.
Jin YN; Chung HK; Kang JH; Lee YJ; Kimm KI; Kim YJ; Kim S; Chung JK
Cancer Biother Radiopharm; 2008 Oct; 23(5):551-60. PubMed ID: 18986218
[TBL] [Abstract][Full Text] [Related]
19. Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I.
Tang J; Wang X; Xu Y; Shi Y; Liu Z; Yang Y
Technol Cancer Res Treat; 2015 Feb; 14(1):61-9. PubMed ID: 24354753
[TBL] [Abstract][Full Text] [Related]
20. Specific activation of sodium iodide symporter gene in hepatoma using alpha-fetoprotein promoter combined with hepatitis B virus enhancer (EIIAPA).
Liu RS; Hsieh YJ; Ke CC; Chen FD; Hwu L; Wang FH; Hwang JJ; Chi CW; Lee CH; Yeh SH
Anticancer Res; 2009 Jan; 29(1):211-21. PubMed ID: 19331152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
